Rationale: Transgenic mice with cardiac specific overexpression of mutated ␣B-crystallin (CryAB R120G ) display Desmin-related myopathy (DRM) with dilated cardiomyopathy and heart failure. Our previous studies showed the presence of progressive mitochondrial abnormalities and activation of apoptotic cell death in CryAB R120G transgenic hearts. However, the role of mitochondrial dysfunction and apoptosis in the overall course of the disease was unclear. Objective: We tested the hypothesis that prevention of apoptosis would ameliorate CryAB R120G pathology and decrease morbidity. Methods and Results: We crossed CryAB R120G mice to transgenic mice with cardiac specific overexpression of Bcl-2. Sustained Bcl-2 overexpression in CryAB R120G hearts prolonged CryAB R120G transgenic mice survival by 20%. This was associated with decreased mitochondrial abnormalities, restoration of cardiac function, prevention of cardiac hypertrophy, and attenuation of apoptosis. CryAB R120G misfolded protein aggregation was significantly reduced in the double transgenic. However, inhibition of apoptotic signaling resulted in the upregulation of autophagy and alternative death pathways, the net result being increased necrosis. Key Words: heart disease Ⅲ mitochondria Ⅲ apoptosis Ⅲ protein misfolding Ⅲ autophagy Ⅲ necrosis T he R120G mutation in ␣B-crystallin (CryAB R120G ) causes Desmin-related myopathy (DRM). 1 A mouse model of DRM, created by cardiomyocyte-specific overexpression of CryAB R120G , develops progressive dilated cardiomyopathy followed by a transition to heart failure (HF). 2 We have previously shown that this model of DRM is characterized by early mitochondrial dysfunction and activation of intrinsic (mitochondrial-based) apoptotic signaling. 3 Although apoptotic cell death can directly cause HF, 4
T he R120G mutation in ␣B-crystallin (CryAB R120G ) causes Desmin-related myopathy (DRM). 1 A mouse model of DRM, created by cardiomyocyte-specific overexpression of CryAB R120G , develops progressive dilated cardiomyopathy followed by a transition to heart failure (HF). 2 We have previously shown that this model of DRM is characterized by early mitochondrial dysfunction and activation of intrinsic (mitochondrial-based) apoptotic signaling. 3 Although apoptotic cell death can directly cause HF, 4 the sufficiency of apoptosis for DRM-mediated HF specifically, and in protein-conformation based heart disease in general has not been explored.
The intrinsic pathway of apoptosis is regulated by the Bcl-2 family, 5 with Bcl-2 being the antiapoptotic founding member. 6 Complex interactions between Bcl-2 family members, such as Bak and Bax can result in permeabilization of the mitochondrial outer membrane. 7 Together with mitochondrial permeability transition pore (MPTP) opening, these 2 processes appear to be a general and, in most cases, terminal commitment step for the decision between cell life and death. 8 It is still unclear as to how Bcl-2 protects cells from apoptotic death. Recent studies in experimental animal models demonstrated that overexpression of Bcl-2 prevents apoptosis and injury of cardiomyocytes in after ischemia/reperfusion hearts. 9, 10 In addition, high levels of Bcl-2 were sufficient to prevent mitochondrial and contractile dysfunction in desmin null mice. 11 Apart from its antiapoptotic function, Bcl-2 also regulates release of Ca 2ϩ from the endoplasmic reticulum and reduces mitochondrial Ca 2ϩ uptake. 12, 13 We wished to define the role of apoptosis in DRM pathology and determine the effects of blocking the intrinsic apoptotic pathway in terms of impacting on DRM. By crossing the CryAB R120G mice with transgenic (TG) mice harboring cardiac restricted overexpression of Bcl-2, 9 we asked whether Bcl-2 overexpression could decrease or abolish apoptosis in the CryAB R120G cardiomyocytes and if inhibition of apoptosis was sufficient to prevent HF. We found that, in addition to preventing mitochondrial swelling, Bcl-2 overexpression resulted in the upregulation of autophagy, which in turn led to increased elimination of misfolded protein aggregates and a reduction in their overall accumulation. Cardiac-restricted overexpression of Bcl-2 in the CryAB R120G mice attenuated cardiomyocyte apoptosis by blocking the intrinsic cell death pathway, but did not prevent their ultimate death as the death process shifted toward necrosis.
Methods

Transgenic Mice
CryAB R120G mice and Bcl-2 overexpressing mice were used as described previously, 2, 9 except that the Bcl-2 TG mice were first was bred into the FVB/N background by back-crossing the original Bcl-2 TGs to FVB/N animals for at least 7 generations. Three experimental groups were studied: single CryAB R120G , Bcl-2 overexpressing double TG CryAB R120G /Bcl-2, and age matched nontransgenic (NTG) littermates. TG and double TG mice were identified by PCR analysis of genomic DNA isolated from tail clips. Animals were housed in a facility approved by the Association for Assessment and Accreditation of Laboratory Animal Care, and experiments were approved by the Institutional Animal Review Board.
Antibodies and Reagents
Anti-tubulin and polyclonal anti-receptor-interacting protein (RIP)1 were purchased from Santa Cruz Biotechnology, anti-caspase-3 was from Cell Signaling, and monoclonal anti-RIP1 was purchased from BD Biosciences. Anti-Beclin 1 was obtained from Stressgen, and anti-light chain (LC)3 from Novus. Recombinant human tumor necrosis factor (TNF) was purchased from Sigma.
Evans Blue Staining
Fluorescent staining with Evans blue dye (EBD) was used to assess the impairment of sarcolemmal membrane integrity. Six-month-old mice were injected with EBD (10 mg/mL in PBS) intraperitoneally with 0.1 mL per 10 g of body weight. Twenty-four hours later heart tissue was embedded in OCT Tissue Tek (Sakura Finetechnical), and snap-frozen in liquid nitrogen. Seven-m sections were cut, washed with PBS, and counterstained by phalloidin (Invitrogen). Stained sections were visualized using the fluorescent microscope, and areas of red auto-fluorescence (EBD positive areas) were selected and imaged.
Cell Culture
3T3 fibroblasts were cultured in DMEM supplemented with 10% FCS and antibiotics (25 U/mL penicillin, 25 g/mL streptomycin) (Invitrogen) in 5% CO 2 in air at 37°C. Replication-deficient adenoviruses for CryAB R120G and Bcl-2 were generated using the AdEasy adenoviral system (Stratagene). Cells were typically infected with adenovirus at a multiplicity of infection of 10 for 2 hours at 37°C. The cells were then cultured for a further 24 hours in virus-free media before treatment. Cell death was induced with 10 ng/mL of TNF for 10 minutes. For cell death analysis, the Cell Proliferation Kit from Roche was used according to the protocol of the manufacturer.
For autophagy assays, rat neonatal cardiomyocytes were used. Cells were plated 24 hours before the infection. On the next day, cells were infected with GFP-LC3 adenovirus (provided by J. Sadoshima, University of Medicine and Dentistry of New Jersey), in combination either with AD-CryAB R120G , AD-Bcl-2, or both. Fortyeight hours later, cells were washed, fixed, visualized by fluorescent microscope and analyzed by Image Stream.
Mitochondrial Swelling and Complex I Activity
Mitochondrial swelling experiments were performed as described previously. 3 Complex I activity was measured as described. 14 Fifty g of isolated heart mitochondria were diluted in the reaction mixture consisted of 250 mmol/L sucrose, 1.0 mmol/L EDTA, 50 mmol/L Tris-HCl, pH 7.4, 10 mol/L decylubiquinone (Sigma), and 2 mmol/L KCN. The reaction was initiated by adding 50 mol/L NADH, and monitored continuously at a wavelength of 272 minus 247 nm at 30°C for 1 minute. Rotenone (5 g) was added, and any rotenone-insensitive activity was measured for 1 minute.
ImageStream Data Acquisition and Analysis
This fluorescence image-based method for quantifying LC3 relies on differentiating the diffuse and punctate forms of LC3 staining. Cells infected with adenovirus carrying GFP-LC3 were coinfected with AD-CryAB R120G , AD-Bcl-2, or both. Forty-eight hours after infection, cells were trypsinized, fixed, excited with a 488-nm laser light and imaged on a time delay integration CCD camera. Images of fixed cells collected on the ImageStream (Amnis), were analyzed using ImageStream Data Exploration and Analysis Software (IDEAS). Because fluorescent probes have broad emission spectra, spectral compensation was digitally performed on a pixel-by-pixel basis before data analysis. After compensation, similarity analysis and spot counting was done on in-focus single cell images. Three samples from each group were analyzed using 10 000 cells per sample.
Statistical Analysis
All data are expressed as meansϮSE. Comparisons between experimental were determined by 1-way or 2-way ANOVA where appropriate, followed by Student's t test. A probability value of Ͻ0.05 was considered statistically significant.
Results
Overexpression of Bcl-2 Increases Lifespan and Ameliorates Cardiac Dysfunction in CryAB R120G Mice
Mice that overexpress Bcl-2 specifically in the cardiomyocytes have been described. 8 We crossed those mice repeatedly into the FVB/N background, the strain in which our other transgenic mice were made, to avoid strain specific phenotypes. Cardiomyocyte-restricted Bcl-2 overexpression in an FVB/N background was benign with no effects observed on heart structure or function (data not shown). The Bcl-2 transgene continued to be strongly expressed in the hearts of the FVB/N strain ( Figure 1A ) and when it was crossed into the CryAB R120G background as well ( Figure 1A) , with quantitation of the signals indicating overexpression levels of Ϸ5-fold in animals carrying 1 copy of the Bcl-2 transgene and 9-fold in animals with 2 copies (homozygous for the transgene). We used double transgenic animals that carried 1 copy of each transgene (Bcl-2 and CryAB R120G ) for all experiments to avoid any effects attributable to insertional mutagenic events. As shown previously, cardiac-restricted expression of CryAB R120G leads to premature lethality by the age of 7 to 8 months ( Figure 1B) all of these mice also died prematurely with no survivors by 8.5 to 9 months of age ( Figure 1B ). We previously showed that overexpression of CryAB R120G contributes to the LV dysfunction characterized by the progressive transition from concentric hypertrophy to dilated cardiomyopathy at the age of 6 months. 2 In association with their prolonged lifespan, CryAB R120G /Bcl-2 mice displayed an attenuated cardiac hypertrophic response ( Figure 1C ). To determine whether overexpression of Bcl-2 was sufficient to attenuate adverse cardiac remodeling in CryAB R120G mice, we examined cardiac structure using standard morphometric analyses and 2D-directed M-mode echocardiography ( Figure  1C and the Table) . Figure 1B shows that heart weight-to-body weight ratios of the single CryAB R120G mice at 4 and 6 months were significantly greater than age-matched NTG and CryAB R120G /Bcl-2 mice. In addition, marked disparities in cardiac function between the CryAB R120G and CryAB R120G / Bcl-2 mice were apparent as well (Table) . At 6 months of age, when the CryAB R120G animals were already in failure, the heart rate and shortening fraction of the CryAB R120G /Bcl-2 mice were conserved with significantly better LV function (Table) .
Bcl-2 Expression Prevents Mitochondrial Swelling and Blunts the Apoptotic Response in CryAB R120G Mice
Constitutive overexpression of mutant CryAB R120G leads to mitochondrial dysfunction, a precocious and lasting 50% reduction in Complex I activity, opening of the MPTP and activation apoptotic cell death. 3 MPTP opening results in mitochondrial swelling and irreversible loss of the matrix and intermembrane content. 8 If this cannot be prevented, the outer mitochondrial membrane will eventually rupture, releasing potent apoptogens into the cytoplasm and triggering apoptotic cell death. Proapoptotic members of the Bcl-2 family such as Bax and Bak play important roles in mediating mitochondrial swelling. Because the antiapoptotic family members, Bcl-2 and Bcl-XL are able to prevent the permeabilization of the outer mitochondrial membrane by directly inhibiting Bax and Bak, 15 we first analyzed this potential beneficial effect in the CryAB R120G /Bcl-2 hearts. Mitochondria isolated from 2-month-old CryAB R120G mice were extremely sensitive to Ca 2ϩ -induced swelling, 3 but the mitochondria derived from the CryAB R120G /Bcl-2 mice were essentially normal ( Figure  2A ). At the same time, mitochondrial complex I activity in the CryAB R120G /Bcl-2 hearts showed the same deficits apparent in the CryAB R120G -derived material, showing that Bcl-2 overexpression is not able to rescue the respiratory deficits in the CryAB R120G mitochondria ( Figure 2B ). To begin to explore the mechanisms responsible for Bcl-2-mediated attenuation of cardiomyocyte apoptosis we evaluated the extent of DNA fragmentation longitudinally in the NTG, CryAB R120G and CryAB R120G /Bcl-2 hearts by quantitating TUNEL-positive nuclei located in identified cardiomyocytes. We observed significant decreases in the number of TUNEL-positive nuclei in 2-and 6-month-old CryAB R120G /Bcl-2 hearts as compared to CryAB R120G ( Figure 2C ). We confirmed that we were observing decreases in apoptosis by measuring reduced levels of activated caspase-3 in the CryAB R120G /Bcl-2 but not in CryAB R120G hearts ( Figure 2D ). We then measured the release of cytochrome c from mitochondria into the cytosol in the hearts of 5-month-old CryAB R120G and CryAB R120G /Bcl-2 mice. Representative Western blots derived from the mitochondrial and cytosolic proteins showed that in CryAB R120G /Bcl-2 mouse hearts, cytosolic cytochrome c levels were significantly lower than in the CryAB R120G hearts although they remained higher than the level observed in the NTG littermates ( Figure 2E ).
Protein Aggregation in CryAB
R120G
/Bcl-2 Mice Is Reduced
CryAB R120G -mediated DRM is a protein misfolding disease characterized by accumulation of insoluble protein depositions, whose accumulations can have both toxic 14 and protective functions. 16 Although expression of Bcl-2 in the CryAB R120G hearts did not completely prevent aggregate formation, electron microscopy revealed major disparities in protein deposition architecture. The aggresomes 16, 17 in the CryAB R120G hearts appeared to be largely homogenous, consisting of uniformly solid, granulofilamentous bodies, whereas in the CryAB R120G /Bcl-2 hearts, they appeared as heterogeneous masses of small electron-dense material interspersed with mitochondria ( Figure 3A) . Immunofluorescent staining for CryAB was used to quantitate the cytoplasmic area occupied by the aggresomes ( Figure 3B ) and confirmed significant decreases in their accumulation at all ages measured ( Figure 3C ).
Protein aggregates may form by abnormal folding or by disturbance of intracellular protein degradation pathways. Although autophagy is known to play a critical role in the major degradation pathways for cellular protein and organelles, it is becoming increasingly apparent that autophagy is an important cellular process that can be activated in response to the accumulation of misfolded proteins. 18 Autophagy is upregulated in rat neonatal cardiomyocytes infected with CryAB R120G adenovirus and blunting autophagy in CryAB R120G hearts accelerated and increased development of the cardiac pathology. 19 Given those data and the observation that CRYAB R120G / Bcl-2 hearts displayed significant decreases in protein aggregate levels, we wished to evaluate and compare the autophagic response in CryAB R120G and CryAB R120G /Bcl-2 hearts. Beclin 1 is considered to be a key player in autophagy. Beclin 1 promotes autophagic activity 20 and is involved in the recruitment of membranes to form the autophagosome. However, in contrast to our expectation that autophagy would be increased in both the CryAB R120G and CryAB R120G /Bcl-2 hearts, we observed modest but significant reductions in Beclin 1 levels in both the CryAB R120G and CryAB R120G / Bcl-2 hearts relative to NTG ( Figure 4A ).
Given the complex nature of autophagy, we analyzed additional markers of the process. Formation and maturation of autophagosomes is accompanied by intracellular translocation and processing of microtubule-associated protein 1 LC3, 21 an important component of the autophagosome membrane and one of the most reliable markers of autophagy. Western Blot analysis showed accumulation of cleaved LC3-II exclusively in the hearts of CryAB R120G / Bcl-2 but not CryAB R120G mice, suggesting a significant augmentation of an autophagic response in the double transgenic mice ( Figure 4B ).
To gain a qualitative assessment of autophagy, we carried out transmission electron microscopy on hearts derived from the single and double transgenic hearts at 5 months. As expected, the CryAB R120G hearts showed the usual pathology at this stage with significant accumulations of large, granulofilamentous aggregates, disrupted mitochondria with massive cristae lysis and sarcomere disruption. However, strikingly, there was a paucity of any structures that could be identified as either intermediates or late stages in the autophagic pathway ( Figure 5A ). In contrast, the fields from the double transgenic hearts contain numerous intermediates/ participants in the autophagic pathway, including amphisomes, the autophagic vacuoles formed on fusion between autophagosomes and endosomes, lysosomes and autolysosomes ( Figure 5B through 5D) . R120G and CryAB R120G /Bcl-2 hearts. B, Immunofluorescence staining for CryAB (green) with troponin I counterstaining (red) shows decreased aggregate levels. C, Time-dependent quantification of CryAB aggregates using MetaMorph software shows a decreased slope for aggregate accumulation in CryAB R120G /Bcl-2 hearts. *PϽ0.05 vs CryAB R120G . R120G and CryAB R120G /Bcl-2 mice. A, Representative Western Blot images and quantification for Beclin 1 in 6-month-old CryAB R120G and CryAB R120G /Bcl-2 hearts. B, Appearance of LC3II as a marker of autophagy. Western Blots were probed with anti-LC3 antibody. Tubulin was used as a loading control (nϭ4). To quantitate the increase in autophagic activity in response to Bcl-2 overexpression, neonatal rat cardiomyocytes were infected with GFP-LC3 autophagy-reporter adenovirus, followed by infection with AD-CryAB R120G , AD-Bcl-2, or a combination of both. Forty-eight hours later cells were fixed, visualized by fluorescent microscopy and analyzed using the Image Stream system (Figure 6 ). LC3 undergoes a significant redistribution during autophagy, changing from a diffused cytosolic signal to punctate dots that mark the mature autophagosome. 22 After 48 hours, the abundance of punctuated LC3 was almost 5-fold higher in the cardiomyocytes infected with both AD-Bcl-2 and AD-CryAB R120G in comparison to AD-CryAB R120G only ( Figure 6B ). Blockade of autophagosome formation using 3-MA significantly reduced the accumulation of punctuated LC3 in R120G/Bcl-2 infected cardiomyocytes.
Figure 4. Autophagy in CryAB
Blunting the Apoptotic Response Leads to Necrosis in CryAB
R120G
/Bcl-2 Mice
Our data showed that overproduction of the antiapoptotic protein Bcl-2 increased the lifespan of the CryAB R120G animals, indicating that the intrinsic apoptotic pathway does play a pathogenic role in DRM. However, the animals still die prematurely, so abrogation of apoptosis is clearly not sufficient to rescue the phenotype. Historically, apoptosis has been defined as a type of cell death that is morphologically distinct from other types of cell death such as necrosis. 23 Despite the long held view that necrosis is an accidental and uncontrolled form of cell death, recent studies have revealed that necrosis is probably tightly controlled, and intriguing interactions between the apoptotic and necrotic machinery have been uncovered. 24 Eliminating genes encoding proteins controlling apoptosis resulted in the conversion of an apoptotic phenotype to a necrotic one, both in vitro and in vivo. 25 We hypothesized that by overexpressing Bcl-2 and decreasing apoptotic flux in the absence of not affecting the primary genetic lesion (expression of CryAB R120G ); we might have shifted the cell death balance to necrosis.
EBD analyses were performed to detect necrotic cell death-related membrane abnormalities in the myocardium of NTG, CryAB R120G and CryAB R120G /Bcl-2 hearts (Figure 7A) . NTG cardiomyocytes were impervious to EBD (not shown). In the hearts from 6 month CryAB R120G mice, which are undergoing extensive apoptotic cell death, 3 sporadic EBD-positive myocytes were observed ( Figure  7A ). However, the number of EDB-positive cells in CryAB R120G /Bcl-2 hearts were significantly increased ( Figure 7A , bottom, and 7B).
Pharmacological and genetic evidence suggests that necrosis can occur in a tightly regulated manner. 26 Cell death inducers such as TNF promote either apoptosis or necrosis depending on the specific experimental setting. 27 When apoptotic cell death is inhibited by antiapoptotic factors, a process of programmed necrotic death can occur. 28 Although the proteins regulating necrosis are largely undefined, recent data indicate that some regulatory mechanisms may be shared or intersect with apoptosis, 29 and RIP1 kinase may play an important role in deciding between necrosis and survival when the apoptotic signal is blocked. 29 Consistent with this hypothesis, we found significantly higher RIP1 levels in 6-month-old CryAB R120G /Bcl-2 hearts compared to NTG and CryAB R120G samples ( Figure 7C and 7D) . Interestingly, CryAB R120G hearts showed markedly reduced RIP1 levels. We tested the hypothesis that coexpression of Bcl-2 and CryAB R120G is sufficient to cause increased levels of RIP1. 3T3 cells were infected with adeno-CryAB R120G (R group), adeno-Bcl-2 (B group), or with both (RB group) and RIP1 accumulation determined 24 hours later by immunohistochemistry (Online Figure I, A, in the Online Data Supplement, available at http://circres.ahajournals.org). Confirming the hypothesis, RB cells showed more than a 7-fold accumulation of RIP1 compared to R, B and control cells (Online Figure I, B) .
We next tested whether accumulation of RIP1 was sufficient to increase the sensitivity of infected 3T3 cells to TNF-mediated necrosis (Online Figure I, C) . Cells were treated with low levels of TNF (Methods) and the level of cell death was evaluated. Whereas nontransfected R120G and Bcl-2-infected cells showed only minor responses to TNF, cell death in RB cells increased by 100%, indicating a significantly elevated sensitivity of RB cells to TNFmediated necrosis. However, when the effect of TNF was analyzed in the presence of necrostatin, a specific inhibitor of RIP1, the sensitizing effect was completely abrogated.
Discussion
Several etiologic factors have been linked to the onset and development of dilated cardiomyopathy and HF in the CryAB R120G mice. These include mitochondrial abnormalities, myofilament disarray, reduction in contractile function attributable to accumulation of insoluble aggregates, and apoptotic cell loss. 3, 14, 17, 30 Each of these parameters contributes to CryAB R120G cardiac pathogenesis. In this study, we wished to explore the role of apoptosis in the progression of HF in CryAB-mediated DRM and took a genetic approach to inhibit cardiomyocyte apoptosis by driving overexpression of antiapoptotic Bcl-2 in the hearts of CryAB R120G mice. There are considerable data suggesting that apoptotic cell death can play an important or even determining role in progressive cardiac remodeling, 31, 32 with overexpression of either intrinsic or extrinsic apoptotic pathway components causing dilated cardiomyopathy. 28 Previous studies suggest a beneficial effect for increased Bcl-2 expression in different genetic models of cardiomyopathy, including the desmin nulls, a model of ischemic/reperfusion injury, as well as in CryAB R120G mice with cardiac restricted overexpression of secretable TNF. 10, 11, 31 We show here that overproduction of Bcl-2 in the heart not only reduces the level of CryAB R120G -induced cardiac apoptosis but also impacts, albeit temporarily, on adverse cardiac remodeling, progressive hypertrophy and decreased fractional shortening. Although abrogation of apoptosis slows loss of cardiac function, it does not halt a pathogenic progression that results in eventual dilation and HF.
In addition to clarifying the role of apoptosis in this model, our data provide several new insights into the mechanism of CryAB R120G -mediated pathology. As is the case for most protein conformation-based disease, CryAB R120G -DRM is characterized by the accumulation of abnormal protein aggregates. 2 Autophagy can be involved in the intracellular degradation of aggregation-prone proteins, such as ␣-synuclein and huntingtin, 33, 34 and Beclin 1 is one of the key players in autophagosome formation. 35 However, despite the increase in the number of lysosomes and autophagosomes in both CryAB R120G and CryAB R120G /Bcl-2 mice, the level of Beclin 1 was significantly reduced in these models. This is in agreement with studies from other groups showing Beclin 1 reduction in other protein misfolding diseases such as Alzheimer or Huntington. 36 How Beclin 1 is regulated in cardiomyocytes and why it is decreased in the latter stages of the DRM model remains unclear. Overexpression of mutant CryAB R120G itself did not directly result in reduced Beclin 1 levels. However, the BH3 domain of Beclin 1 can bind directly to Bcl-2, 37 with the interaction actually inhibiting autophagy but leaving the antiapoptotic activity of Bcl-2 intact. 38 In beginning to ask how overexpression of Bcl-2 affects the autophagic status of CryAB R120G mice, we find it intriguing that critical players in the apoptotic and autophagic pathways can interact. Unlike other studies showing the antiautophagic activity of Bcl-2, 39 the autophagic response remained largely intact as evidenced by increased LC3-II levels and the significant reduction in protein aggregate accumulation. Activation of autophagy under conditions of inhibited apoptotic cell death has been previously documented in Bak/Bax knockout mice. 40 The precise role of autophagy in the progression of HF remains unclear. In some HF models, amplification of the autophagic response led to pathological hypertrophy, decreased cardiac performance, and promotion of autophagic cell death. 41 In other studies, autophagy protected the heart by scavenging and eliminating misfolded proteins. 42 It appears that autophagy can lead to different outcomes depending on disease context and severity. Future studies using genetic approaches are underway to define the exact role of autophagy in our model at the different disease stages.
Necrosis has been often viewed as an accidental and unregulated event but data are now rapidly accumulating that suggest necrosis can also be thought of as programmed cell death. 43 The cell death program, whether by apoptosis or by necrosis, is mediated through an integrated cascade, which can be assessed at multiple junction sites and propagated through numerous branch points. 29 Recent studies point to RIP1 as a possible "molecular switch" that can determine whether the cell succumbs through apoptosis or necrosis. 44 In our model, overproduction of Bcl-2 led to increased RIP1 with a concomitant increase in necrosis and these admittedly preliminary but intriguing data point the way for further exploration of whether these markers are general or more specific to different but related cell death processes.
That overexpression of Bcl-2 leads to a reversal of calcium sensitivity of the mitochondria and may lead to a switch from apoptosis to autophagy and necrosis argues strongly for the existence of complex regulatory interactions between these scavenger/cell death mechanisms and could explain the limited success of antiapoptotic therapies. An additional complication is the different roles these processes could play at different times in disease progression and presentation. Although considerable work will be required to explain the observations outlined in this article, an appreciation of the
Novelty and Significance
What Is Known?
• Mutations in ␣B-crystallin can cause a dilated cardiomyopathy and heart failure.
• Although apoptotic cell death contributes to the development of cardiac pathology, its necessity and sufficiency in the cardiac pathogenesis is not known.
What New Information Does This Article Contribute?
• In vivo evidence that death pathways other than apoptosis are capable of causing cardiomyopathy and heart failure in this animal model.
• This is the first demonstration in this animal model showing that abrogation of the intrinsic pathway of apoptosis in the heart is possible and that, although life is prolonged, the animal still dies prematurely.
• Indirectly supports a model for the interlinking of different death pathways in the pathogenic process that leads to cardiac death.
The missense R120G mutation in the small heat shock protein ␣-B-crystallin (CryABR120G) causes a desmin-related myopathy (DRM). This skeletal and cardiac disease is characterized by the formation of desmin-and CryAB-containing aggregates within muscle fibers, including those within the heart. Mice with cardiac-specific overexpression of CryABR120G develop severe cardiomyopathy at 3 months of age and die at 6 to 7 months from heart failure. Previous studies showed that overexpression of CryABR120G results in formation of perinuclear aggresomes, and accumulation of preamyloid oligomer. Preamyloid oligomer is considered to be the cytotoxic entity in many of protein misfolding-based diseases, and we noted extensive apoptosis in these hearts. Because of this, we asked whether we could impact materially on disease progression by interfering with apoptosis and so, we crossed the CryABR120G mice with a mouse that specifically expressed the antiapoptotic molecule, Bcl-2, in cardiomyocytes. To our surprise, although apoptosis was largely ameliorated, the mice still died although they lived 20% longer than mice that did not express increased levels of Bcl-2. To understand the cause of death, we explored whether other death pathways were activated and found that, indeed, although apoptosis was shut down, necrosis was activated. These findings have implications for using the death pathways as therapeutic targets and indicate that multiple pathway interactions will need to be considered and tested for any potential therapeutics aimed at a single pathway.
